ATS 2022 International Annual Conference

San Francisco - Moscone Center

May 13-18, 2022

Learn how we are transforming the field of lung health at booth 709

Stop by our booth to:

  • Experience our trusted portfolio and latest technologies
  • Test your skills with our ENB virtual reality experience
  • See a patient management platform demo
  • Ask questions and engage with our team of product experts
Seeing is Believing — Experience a virtual reality ILLUMISITE™ platform procedure to see the difference!
Join us in the booth to experience, for the first time, the ILLUMISITE™ platform with virtual reality!
Join our live events at ATS 2022
Innovation Suite

Sign up to help guide our future product innovations — we will have areas for feedback and interaction on pipeline products! This interaction is estimated to take 30-60 minutes and will require signing a confidentiality agreement.

Sunday, May 15 and Monday, May 16 10:30a.m. -3:30p.m.
ILLUMISITE™ platform — dynamic imaging for a dynamic environment 
Learn how the ILLUMISITE™ platform has overcome CT-to-body divergence. Degrees of accuracy make all the difference. Case reviews and clinical discussion with Bryan Benn, M.D. and Luke Seaburg, M.D.

Saturday, May 14, 7:00 p.m.
Don’t miss the chance to hear from Mr. Kelvin Lau as he presents his abstract on microwave ablation
As part of the RAPiD: Rapid Abstract Poster Discussion Session of the ATS agenda, Mr. Kelvin Lau from St. Bartholomew’s Hospital, London, UK will be presenting: B110: The Midas Touch Interventional Pulmonology in Thoracic Oncology, showcasing his abstract Long Term Outcomes of Bronchoscopic Microwave Ablation of Peripheral Lung Nodules.††

Monday, May 16
2:15 p.m. - 3:45 p.m.
Featured at ATS 2022, booth 709: Medtronic Lung Health Solutions innovative product portfolio
ILLUMISITE™ Platform
Correct for CT-to-body divergence, even in smaller nodules. Better visualize smaller lung lesions.1-5,† Biopsy with greater confidence.6 It’s all possible with our fluoroscopic navigation technology, continuous guidance, and innovative tools.

LungGPS™ Patient Management Platform

Designed to assist clinicians in identifying incidental nodules and monitoring lung nodule patients, manage workflows, and streamline thoracic tumor board collaboration.
Meet the team

Get in touch with a Medtronic product expert or your local account manager to find the right solutions for you, your patients, and your facility.
† Not evaluated in lesions < 10 mm.

†† Emprint is only available in EU and Hong Kong.

1. Aboudara M, Roller L, Rickman O, et al. Improved diagnostic yield for lung nodules with digital tomosynthesis corrected navigational bronchoscopy: Initial experience with a novel adjunct. Respirology. 2019. doi:10.1111/ resp.13609.

2. Bhadra K, Mattingley J, Pritchett M. Electromagnetic navigation bronchoscopy with advanced fluoroscopy-based localization and intraprocedural local registration for the evaluation of peripheral pulmonary nodules. Paper presented at: CHEST Annual Meeting; Oct. 23, 2019; New Orleans, LA.

3. Pritchett MA, Bhadra K, Mattingley JS. Electromagnetic navigation bronchoscopy with tomosynthesis-based visualization and positional correction: three-dimensional accuracy as confirmed by cone-beam computed tomography. J Bronchol Interv Pulmonol. 2021;28:10–20. doi: 10.1097/LBR.0000000000000687

4. Avasarala SK, Roller L, Katsis J, et al. Sight Unseen: Diagnostic Yield and Safety Outcomes of a Novel Multimodality Navigation Bronchoscopy Platform with Real-Time Target Acquisition. Respiration. 2021; doi: 10 .1159 /000518009.

5. Dunn BK, Blaj M, Bowling M, et al. Evaluation of Electromagnetic Navigational Bronchoscopy Using Tomosynthesis-Assisted Visualization, Intraprocedural Positional Correction and Continuous Guidance for Evaluation of Peripheral Pulmonary Nodules. J Bronchology Interv Pulmonol. Published online Mar 10, 2022. doi:10.1097/LBR.0000000000000839.

6. Based on internal report #DGR00596, A summative survey results report; 16 physicians surveyed for the ILLUMISITE™ platform. March 2019.


The ILLUMISITE™ platform is indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool.  Not for pediatric use.

WARNING: The ILLUMISITE™ platform may only be used by a qualified bronchoscopist.

CONTRAINDICATIONS: Flexible bronchoscopy should be performed only when the relative benefits outweigh the risks.

Absolute contraindications include, but are not limited to: lack of adequate facilities and personnel to care for emergencies such as cardiopulmonary arrest, pneumothorax, or bleeding, inability to adequately oxygenate the patient during the procedure.

Conditions that are usually considered absolute contraindications, unless risk-benefit assessment warrants the procedure: Coagulopathy or bleeding diathesis that cannot be corrected, severe obstructive airways disease, severe refractory hypoxemia, unstable hemodynamic status including dysrhythmias. Relative contraindications or conditions involving increased risk include but are not limited to: Recent myocardial infarction or unstable angina, uremia and pulmonary hypertension, and known or suspected pregnancy. Please refer to Instructions for Use for complete contraindication and risk information. 

 
The LungGPS™ patient management platform is only available for sale in the United States.

The LungGPS™ patient management platform is an information management software only and does not diagnose or treat lung cancer nor replace lung cancer assessment in standard clinical practice. LungGPS™ should be used in conjunction with professional guidelines for patient management decision.

Contraindications: LungGPS™ is intended to integrate with specific file output of sequencing instruments such as Illumina sequencers as well as integrate with specific electronic medical records and external database warehouses. The system should not be used with any instruments that have not been tested and verified as compatible with LungGPS™.

 
©2022 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 04/2022–US-RE-2200223